Who Generates Higher Gross Profit? Jazz Pharmaceuticals plc or Supernus Pharmaceuticals, Inc.

Jazz Pharmaceuticals leads in gross profit over Supernus.

__timestampJazz Pharmaceuticals plcSupernus Pharmaceuticals, Inc.
Wednesday, January 1, 20141055457000116287000
Thursday, January 1, 20151222277000136004000
Friday, January 1, 20161382587000203017000
Sunday, January 1, 20171508505000287023000
Monday, January 1, 20181769378000393541000
Tuesday, January 1, 20192033831000376095000
Wednesday, January 1, 20202214650000467938000
Friday, January 1, 20212653478000504714000
Saturday, January 1, 20223118857000580017000
Sunday, January 1, 20233398627000523742000
Loading chart...

Infusing magic into the data realm

A Tale of Two Pharmaceutical Giants: Jazz vs. Supernus

In the competitive world of pharmaceuticals, gross profit is a key indicator of a company's financial health and market prowess. From 2014 to 2023, Jazz Pharmaceuticals plc has consistently outperformed Supernus Pharmaceuticals, Inc. in generating gross profit. Jazz's gross profit surged by over 220% during this period, peaking in 2023 with a remarkable $3.4 billion. In contrast, Supernus, while showing steady growth, reached a maximum of $580 million in 2022, marking a 400% increase from its 2014 figures. This stark difference highlights Jazz's dominant market position and strategic advantage. The data underscores the importance of innovation and market strategy in the pharmaceutical industry, where Jazz has clearly excelled. As the industry evolves, these insights provide a glimpse into the financial dynamics shaping the future of healthcare.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025